Area of research
Hematology · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Multiple Myeloma Research and Treatments, Monoclonal and Polyclonal Antibodies Research, Peptidase Inhibition and Analysis, and Chronic Lymphocytic Leukemia Research.
<scp>ChatGPT</scp> as a patient education tool in colorectal cancer—An in‐depth assessment of efficacy, quality and readability
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies
Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action
Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma
58th Annual Conference of Indian Society of Hematology & Blood Transfusion (ISHBT) November 2017, Guwahati, India
DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND SAFETY UPDATE (POLLUX)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma